Global Radiopharmaceuticals Market Size study, by Radioisotope (Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, Lutetium-177), by Source (Nuclear Reactors, Cyclotrons), by Application (Cardiology, Gastroenterology, Oncology, Nephrology, Neurology, Immunology, Others), by End-User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others) and Regional Forecasts 2019-2026
Global Radiopharmaceuticals Market valued approximately USD 5.72 billion in 2018 is anticipated to grow with a healthy growth rate of more than 5.60% over the forecast period 2019-2026. The Radiopharmaceuticals Market is continuously growing in the global scenario at significant pace. Radiopharmaceuticals are a group of pharmaceuticals drug which have radioactivity. It can be used as diagnostic and therapeutic agent. Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical area for diagnosis or therapy. The procedures and facilities for the production, use, and storage of radiopharmaceuticals are subject to licensing by national or regional authorities. Increasing incidence of cardiovascular diseases, growing preference for PET and SPET scans, rise in consciousness about positive effects and enhancements in radiotracers are the substantial driving factors of the market during the forecast period. Moreover, increase in use of radiopharmaceuticals in neurological applications are the factors that likely to create numerous opportunity in the near future. However, scarcity of radioisotopes, strict regulatory standards and high cost of the procedure are the factors that limiting the growth of the market during the forecast period.
The regional analysis of Global Radiopharmaceuticals Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to presence of excellent research facilities and rising healthcare expenditure in the region. Europe is estimated to grow at stable growth rate in the global Radiopharmaceuticals market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to rising demand for PET and SPECT devices and rising patient awareness levels pertaining to cardiovascular diseases and oncology in the region.
The major market player included in this report are:
Advanced Accelerator Applications (AAA)
Bayer AG
Eckert & Ziegler
GE Healthcare
IBA Radiopharma Solutions
Lantheus Holdings Inc.
Mallinckrodt Plc
Nordion Inc.
Positron Corporation
Siemens Healthineers
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Radioisotope:
Technetium-99
Gallium-67
Iodine-123
18F
Rubidium-82
Yttrium-90
Lutetium-177
By Source:
Nuclear Reactors
Cyclotrons
By Application:
Cardiology
Gastroenterology
Oncology
Nephrology
Neurology
Immunology
Others
By End-User:
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Global Radiopharmaceuticals Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
The regional analysis of Global Radiopharmaceuticals Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to presence of excellent research facilities and rising healthcare expenditure in the region. Europe is estimated to grow at stable growth rate in the global Radiopharmaceuticals market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to rising demand for PET and SPECT devices and rising patient awareness levels pertaining to cardiovascular diseases and oncology in the region.
The major market player included in this report are:
Advanced Accelerator Applications (AAA)
Bayer AG
Eckert & Ziegler
GE Healthcare
IBA Radiopharma Solutions
Lantheus Holdings Inc.
Mallinckrodt Plc
Nordion Inc.
Positron Corporation
Siemens Healthineers
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Radioisotope:
Technetium-99
Gallium-67
Iodine-123
18F
Rubidium-82
Yttrium-90
Lutetium-177
By Source:
Nuclear Reactors
Cyclotrons
By Application:
Cardiology
Gastroenterology
Oncology
Nephrology
Neurology
Immunology
Others
By End-User:
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Global Radiopharmaceuticals Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1. Radiopharmaceuticals Market, by Radioisotope, 2016-2026 (USD Billion)
1.3.2. Radiopharmaceuticals Market, by Source, 2016-2026 (USD Billion)
1.3.3. Radiopharmaceuticals Market, by Application, 2016-2026 (USD Billion)
1.3.4. Radiopharmaceuticals Market, by End-User, 2016-2026 (USD Billion)
1.3.5. Radiopharmaceuticals Market, by Region, 2016-2026 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. RADIOPHARMACEUTICALS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. RADIOPHARMACEUTICALS MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. RADIOPHARMACEUTICALS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Key Buying Criteria
4.4. Regulatory Framework
4.5. Investment Vs Adoption Scenario
4.6. Analyst Recommendation & Conclusion
CHAPTER 5. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Radiopharmaceuticals Market, Sub Segment Analysis
5.4.1. Technetium-99
5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2. Gallium-67
5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.3. Iodine-123
5.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.4. 18F
5.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.5. Rubidium-82
5.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.6. Yttrium-90
5.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.7. Lutetium-177
5.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 6. RADIOPHARMACEUTICALS MARKET, BY SOURCE
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Radiopharmaceuticals Market, Sub Segment Analysis
6.4.1. Nuclear Reactors
6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.4.2. Cyclotrons
6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 7. RADIOPHARMACEUTICALS MARKET, BY APPLICATION
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Key Market Players
7.4. Radiopharmaceuticals Market, Sub Segment Analysis
7.4.1. Cardiology
7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.2. Gastroenterology
7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.3. Oncology
7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.4. Nephrology
7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.5. Neurology
7.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.6. Immunology
7.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.7. Others
7.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 8. RADIOPHARMACEUTICALS MARKET, BY END-USER
8.1. Market Snapshot
8.2. Market Performance - Potential Model
8.3. Key Market Players
8.4. Radiopharmaceuticals Market, Sub Segment Analysis
8.4.1. Hospitals
8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2. Ambulatory Surgical Centers
8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3. Diagnostic Centers
8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4. Others
8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 9. RADIOPHARMACEUTICALS MARKET, BY REGIONAL ANALYSIS
9.1. Radiopharmaceuticals Market, Regional Market Snapshot (2016-2026)
9.2. North America Radiopharmaceuticals Market Snapshot
9.2.1. U.S.
9.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.3. Sources breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2. Canada
9.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3. Europe Radiopharmaceuticals Market Snapshot
9.3.1. U.K.
9.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2. Germany
9.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3. Rest of Europe
9.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4. Asia Radiopharmaceuticals Market Snapshot
9.4.1. China
9.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2. India
9.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3. Japan
9.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4. Rest of Asia Pacific
9.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5. Latin America Radiopharmaceuticals Market Snapshot
9.5.1. Brazil
9.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2. Mexico
9.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6. Rest of The World
9.6.1. South America
9.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2. Middle East and Africa
9.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Company Market Share (Subject to Data Availability)
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Advanced Accelerator Applications (AAA)
10.3.1.1. Overview
10.3.1.2. Financial (Subject to Data Availability)
10.3.1.3. Summary
10.3.1.4. Recent Developments
10.3.2. Bayer AG
10.3.3. Eckert & Ziegler
10.3.4. GE Healthcare
10.3.5. IBA Radiopharma Solutions
10.3.6. Lantheus Holdings Inc.
10.3.7. Mallinckrodt Plc
10.3.8. Nordion Inc.
10.3.9. Positron Corporation
10.3.10. Siemens Healthineers
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.1.6. Research Assumption
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1. Radiopharmaceuticals Market, by Radioisotope, 2016-2026 (USD Billion)
1.3.2. Radiopharmaceuticals Market, by Source, 2016-2026 (USD Billion)
1.3.3. Radiopharmaceuticals Market, by Application, 2016-2026 (USD Billion)
1.3.4. Radiopharmaceuticals Market, by End-User, 2016-2026 (USD Billion)
1.3.5. Radiopharmaceuticals Market, by Region, 2016-2026 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. RADIOPHARMACEUTICALS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. RADIOPHARMACEUTICALS MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. RADIOPHARMACEUTICALS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Key Buying Criteria
4.4. Regulatory Framework
4.5. Investment Vs Adoption Scenario
4.6. Analyst Recommendation & Conclusion
CHAPTER 5. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Radiopharmaceuticals Market, Sub Segment Analysis
5.4.1. Technetium-99
5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2. Gallium-67
5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.3. Iodine-123
5.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.4. 18F
5.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.5. Rubidium-82
5.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.6. Yttrium-90
5.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.7. Lutetium-177
5.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 6. RADIOPHARMACEUTICALS MARKET, BY SOURCE
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Radiopharmaceuticals Market, Sub Segment Analysis
6.4.1. Nuclear Reactors
6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.4.2. Cyclotrons
6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 7. RADIOPHARMACEUTICALS MARKET, BY APPLICATION
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Key Market Players
7.4. Radiopharmaceuticals Market, Sub Segment Analysis
7.4.1. Cardiology
7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.2. Gastroenterology
7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.3. Oncology
7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.4. Nephrology
7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.5. Neurology
7.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.6. Immunology
7.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.7. Others
7.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 8. RADIOPHARMACEUTICALS MARKET, BY END-USER
8.1. Market Snapshot
8.2. Market Performance - Potential Model
8.3. Key Market Players
8.4. Radiopharmaceuticals Market, Sub Segment Analysis
8.4.1. Hospitals
8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2. Ambulatory Surgical Centers
8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3. Diagnostic Centers
8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4. Others
8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 9. RADIOPHARMACEUTICALS MARKET, BY REGIONAL ANALYSIS
9.1. Radiopharmaceuticals Market, Regional Market Snapshot (2016-2026)
9.2. North America Radiopharmaceuticals Market Snapshot
9.2.1. U.S.
9.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.3. Sources breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2. Canada
9.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3. Europe Radiopharmaceuticals Market Snapshot
9.3.1. U.K.
9.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2. Germany
9.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3. Rest of Europe
9.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.3.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4. Asia Radiopharmaceuticals Market Snapshot
9.4.1. China
9.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2. India
9.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3. Japan
9.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4. Rest of Asia Pacific
9.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5. Latin America Radiopharmaceuticals Market Snapshot
9.5.1. Brazil
9.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2. Mexico
9.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6. Rest of The World
9.6.1. South America
9.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2. Middle East and Africa
9.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.2. Radioisotope breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.3. Source breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.6.2.5. End-User breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Company Market Share (Subject to Data Availability)
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Advanced Accelerator Applications (AAA)
10.3.1.1. Overview
10.3.1.2. Financial (Subject to Data Availability)
10.3.1.3. Summary
10.3.1.4. Recent Developments
10.3.2. Bayer AG
10.3.3. Eckert & Ziegler
10.3.4. GE Healthcare
10.3.5. IBA Radiopharma Solutions
10.3.6. Lantheus Holdings Inc.
10.3.7. Mallinckrodt Plc
10.3.8. Nordion Inc.
10.3.9. Positron Corporation
10.3.10. Siemens Healthineers
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.1.6. Research Assumption
